The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical significance of serum CA125 kinetics as an early predictor of tumor progression in pancreatic cancer patients.
 
Iori Motoo
No Relationships to Disclose
 
Takayuki Ando
Honoraria - Astellas Pharma; Bristol-Myers Squibb Company; DAIICHI SANKYO COMPANY, LIMITED.; Lilly Japan; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
 
Akira Ueda
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte Japan; Lilly; Merck; MSD; Nihon Servier; Nihon Zouki; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst)
 
Satoshi Yuki
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD K.K; Ono Pharmaceutical; Roche; Taiho Pharmaceutical; Takeda
 
Ken Ito
No Relationships to Disclose
 
Miho Sakumura
No Relationships to Disclose
 
Yuko Ueda
No Relationships to Disclose
 
Yurika Nakayama
No Relationships to Disclose
 
Kohei Nagata
No Relationships to Disclose
 
Shinya Kajiura
Speakers' Bureau - Daiichi Sankyo
 
Nana Kimura
No Relationships to Disclose
 
Kazuto Shibuya
No Relationships to Disclose
 
Tsutomu Fujii
Honoraria - Asahi Kasei; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; EA Pharma; Johnson & Johnson; Kaken Pharmaceutical; Lilly; Miyarisan Pharmaceutical; Otsuka; Taiho Pharmaceutical; TERUMO; Tsumura & Co.
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Covidien/Medtronic (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Kirin (Inst); Lilly (Inst); Miyarisan Pharmaceutical (Inst); MSD (Inst); Otsuka (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TERUMO (Inst); Tsumura & Co. (Inst)
 
Kenichi Hirabayashi
No Relationships to Disclose
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte Japan; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; MSD; Nihon Servier; Nipro Corporation; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; TAKATA Pharmaceutical Co., Ltd; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); BMS (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Jazz Pharmaceuticals (Inst); Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Ichiro Yasuda
No Relationships to Disclose